secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vor Biopharma Inc. (VOR)
CIK:        0001817229
Form:       8-K
Filed at:   2023-06-09T23:59:59+00:00
Accession:  0001193125-23-163990
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vor Bio reports engraftment data from 5 AML patients in trem-cel study; FDA clears VCAR33 ALLO IND
--------------------------------------------------------------------------------

- All 5 trem-cel patients achieved neutrophil engraftment in 10-11 days; high myeloid donor chimerism at day 28.
- Patient 2 had secondary graft failure coincident with coronavirus hKU1 and antimicrobials; backup graft restored engraftment.
- Patient 3 has recovering platelets with autoimmune thrombocytopenia; count 15,000/µL independent of transfusions.
- Patients 4 and 5 had normal engraftment and recovery with no unexpected adverse events; cell doses met release criteria.
- FDA cleared IND for VCAR33 ALLO (allogeneic CAR-T targeting CD33); VBP301 trial to focus on relapsed post-allo-SCT patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817229/000119312523163990/0001193125-23-163990-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817229/000119312523163990/d623996d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-163990

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer